A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
The Phase IIb clinical trial for the CoronaVac® booster dose, sponsored by Sinovac Research and Development Co., Ltd., aims to evaluate the immunogenicity and safety of high and medium doses in healthy adults previously vaccinated with either CoronaVac® or Comirnaty. Given the ongoing global demand for COVID-19 vaccines and booster doses, this trial positions Sinovac to potentially enhance its market share in Turkey and other regions. The competitive landscape includes mRNA vaccines and other inactivated vaccines, necessitating a focus on demonstrating superior immunogenicity and safety profiles to maintain a competitive edge. The trial's suspension due to a change in plans may impact timelines and investor confidence, warranting close monitoring of future developments.
Indication: COVID-19
Modality: vaccine
Target: SARS-CoV-2 virus (inactivated vaccine)
Sponsor: Sinovac Research and Development Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 virus (inactivated vaccine)
View original source fields
Condition raw: COVID-19
Condition normalized: COVID-19
Modality raw: vaccine
Modality normalized: vaccine
Target raw: SARS-CoV-2 virus (inactivated vaccine)
Target normalized: SARS-CoV-2 virus (inactivated vaccine)